Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 4, 2008, Pages 1522-1524

  Nuermberger, Eric ^a,b   Tyagi, Sandeep ^a   Tasneen, Rokeya ^a   Williams, Kathy N ^a   Almeida, Deepak ^a   Rosenthal, Ian ^a   Grosset, Jacques H ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERICIDAL ACTIVITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; FEMALE; MOUSE; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STERILIZING ACTIVITY; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; PYRAZINAMIDE; QUINOLINES; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 42049101775     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00074-08     Document Type: Article

References (7)

1. Matsumoto, M., H. Hashizume, T. Tomishige, M. Kawasaki, H. Tsubouchi, H. Sasaki, Y. Shimokawa, and M. Komatsu. 2006. OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3:e466.
2. Nuermberger, E., I. Rosenthal, S. Tyagi, K. N. Williams, D. Almeida, C. A. Peloquin, W. R. Bishai, and J. H. Grosset. 2006. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 50:2621-2625.
3. Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, R. J. O'Brien, A. N. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169:421-426.
4. Nuermberger, E. L., T. Yoshimatsu, S. Tyagi, K. Williams, I. Rosenthal, R. J. O'Brien, A. A. Vernon, R. E. Chaisson, W. R. Bishai, and J. H. Grosset. 2004. Moxirloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am. J. Respir. Crit. Care Med. 170:1131-1134.
5. O'Brien, R. J., and P. P. Nunn. 2001. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps. Am. J. Respir. Crit. Care Med. 163:1055-1058.
6. Stover, C. K., P. Warrener, D. R. VanDevanter, D. R. Sherman, T. M. Arain, M. H. Langhorne, S. W. Anderson, J. A. Towell, Y. Yuan, D. N. McMurray, B. N. Kreiswirth, C. E. Barry, and W. R. Baker. 2000. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405:962-966.
7. Tyagi, S., E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Ldun is. W. Bishai, and J. Grosset. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49:2289-2293.